Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALEC NASDAQ:EDIT NASDAQ:FDMT NASDAQ:HLVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.56+0.6%$1.42$0.87▼$6.78$154.99M0.74834,645 shs321,134 shsEDITEditas Medicine$2.84+3.3%$2.06$0.91▼$5.91$230.21M2.152.64 million shs2.56 million shsFDMT4D Molecular Therapeutics$4.26+2.4%$3.92$2.24▼$28.93$192.71M2.81803,121 shs319,675 shsHLVXHilleVax$2.12-0.5%$1.96$1.34▼$2.17$106.80M0.76298,907 shs177,155 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector+0.65%-5.45%+3.31%+69.55%-74.34%EDITEditas Medicine+3.27%-7.79%+31.48%+121.01%-52.35%FDMT4D Molecular Therapeutics+2.40%-3.62%-2.52%+39.22%-84.07%HLVXHilleVax-0.47%0.00%+13.98%+25.44%+15.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.835 of 5 stars3.12.00.04.52.72.50.0EDITEditas Medicine4.2326 of 5 stars3.22.00.04.33.72.50.6FDMT4D Molecular Therapeutics2.3641 of 5 stars3.33.00.00.01.91.70.6HLVXHilleVax2.0832 of 5 stars1.05.00.00.03.03.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00156.41% UpsideEDITEditas Medicine 2.31Hold$4.7065.49% UpsideFDMT4D Molecular Therapeutics 2.60Moderate Buy$29.56593.79% UpsideHLVXHilleVax 2.00Hold$2.00-5.66% DownsideCurrent Analyst Ratings BreakdownLatest HLVX, ALEC, EDIT, and FDMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)7/3/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.006/27/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (E+)6/11/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)5/24/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.005/10/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.005/9/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $25.005/9/2025FDMT4D Molecular TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $44.005/9/2025FDMT4D Molecular TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$45.00 ➝ $38.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$100.56M1.55N/AN/A$1.29 per share1.21EDITEditas Medicine$32.31M7.36N/AN/A$1.63 per share1.74FDMT4D Molecular Therapeutics$23K8,580.20N/AN/A$11.05 per share0.39HLVXHilleVaxN/AN/AN/AN/A$3.10 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.18N/AN/AN/A-767,126.06%-33.26%-30.68%8/6/2025 (Estimated)HLVXHilleVax-$147.27M-$2.15N/AN/AN/AN/A-51.86%-41.45%8/14/2025 (Estimated)Latest HLVX, ALEC, EDIT, and FDMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A8/6/2025Q2 2025EDITEditas Medicine-$0.40N/AN/AN/A$1.81 millionN/A8/6/2025Q2 2025FDMT4D Molecular Therapeutics-$0.6922N/AN/AN/A$0.52 millionN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 million5/8/2025Q1 2025FDMT4D Molecular Therapeutics-$0.84-$0.86-$0.02-$0.86$0.53 millionN/A5/8/2025Q1 2025HLVXHilleVax-$0.37-$0.12+$0.25-$0.12N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlector0.103.343.34EDITEditas MedicineN/A3.083.08FDMT4D Molecular TherapeuticsN/A12.3612.36HLVXHilleVaxN/A25.3225.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%EDITEditas Medicine71.90%FDMT4D Molecular Therapeutics99.27%HLVXHilleVax86.42%Insider OwnershipCompanyInsider OwnershipALECAlector9.10%EDITEditas Medicine2.10%FDMT4D Molecular Therapeutics9.60%HLVXHilleVax24.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million90.89 millionOptionableEDITEditas Medicine23083.71 million81.96 millionOptionableFDMT4D Molecular Therapeutics12046.33 million41.88 millionOptionableHLVXHilleVax2050.14 million37.66 millionNot OptionableHLVX, ALEC, EDIT, and FDMT HeadlinesRecent News About These CompaniesHilleVax (HLVX) Upgraded to Strong Buy: What Does It Mean for ... - NasdaqJuly 13, 2025 | nasdaq.comHilleVax (HLVX) Upgraded to Strong Buy: What Does It Mean for the Stock?July 11, 2025 | zacks.comTrium Capital LLP Purchases Shares of 378,205 HilleVax, Inc. (NASDAQ:HLVX)July 9, 2025 | marketbeat.comHilleVax (NASDAQ:HLVX) Shares Down 0.5% - Here's WhyJuly 8, 2025 | marketbeat.comIs HilleVax (NASDAQ:HLVX) In A Good Position To Deliver On Growth Plans?July 3, 2025 | finance.yahoo.comHilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional shareholders who own 51% of the companyMay 22, 2025 | finance.yahoo.comHilleVax, Inc.: HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 9, 2025 | finanznachrichten.deHilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | globenewswire.comHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 28, 2025 | globenewswire.comHillevax CEO Robert Hershberg sells $48,661 in stockFebruary 12, 2025 | msn.comHillevax CFO Shane Maltbie sells $15,116 in stockFebruary 12, 2025 | msn.comHilleVax, Inc. Announces Workforce Reduction and Leadership ChangesDecember 5, 2024 | tipranks.comCautious Hold Rating on HilleVax, Inc: Balancing Strong Cash Reserves with Strategic UncertaintyNovember 12, 2024 | markets.businessinsider.comHilleVax Reports Q3 Financial Results Amid Strategic PlanningNovember 9, 2024 | markets.businessinsider.comHilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback and Strategic ShiftNovember 9, 2024 | markets.businessinsider.comHilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNovember 8, 2024 | manilatimes.netMWhat Makes HilleVax (HLVX) a New Buy StockOctober 14, 2024 | zacks.comHillevax Inc (HLVX) Stock: A Deeper Look at Its True PotentialSeptember 21, 2024 | bovnews.comBHilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)August 29, 2024 | accesswire.comALevi & Korsinsky Investigates Possible Securities Fraud Violations by HilleVax, Inc. (HLVX)August 28, 2024 | accesswire.comAInvestors who lost money on HilleVax, Inc. should contact Levi & Korsinsky about an ongoing investigation - HLVXAugust 27, 2024 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeEV Tax Credits Are Ending—Here’s Why These 2 Stocks Could SoarBy Leo Miller | July 8, 2025View EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could SoarCapitalize on Volatility: 3 Finance Stocks Thriving in 2025By Chris Markoch | July 2, 2025View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025HLVX, ALEC, EDIT, and FDMT Company DescriptionsAlector NASDAQ:ALEC$1.56 +0.01 (+0.65%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.60 +0.04 (+2.56%) As of 07/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Editas Medicine NASDAQ:EDIT$2.84 +0.09 (+3.27%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.82 -0.02 (-0.67%) As of 07/16/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.4D Molecular Therapeutics NASDAQ:FDMT$4.26 +0.10 (+2.40%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$4.20 -0.06 (-1.41%) As of 07/16/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.HilleVax NASDAQ:HLVX$2.12 -0.01 (-0.47%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.10 -0.02 (-0.94%) As of 07/16/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
